Skip to main content
Premium Trial:

Request an Annual Quote

Stephen Turner, Charles Cantor, Erik Wallden, Peter Tattle, Patrick Zenner


Stephen Turner, 58, the co-founder, chairman, and chief executive officer of Frederick, Md.-based Clinomics, will become a non-executive director of Cambridge, UK-based Cytomyx, upon the completion of the acquisition of Clinomics by Cytomyx, the company said. Turner will oversee US operations and business development in the US market.

Charles Cantor will join the scien-tific advisory board of St. Joseph, Mich.-based GeneGo, a bioinformatics firm. Cantor is currently chief scientific officer and a board member of Sequenom. He is also director of the Center for Advanced Biotechnology at Boston University. Cantor has held positions at Columbia University and the University of California at Berkeley, and was director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. In 2002, he founded SelectX Pharmaceuticals.

Erik Wallden will head marketing and business development for Biacore International from Neuchatel, Switzerland, as executive vice president, taking a new position that reports to the president and chief executive officer of the Uppsala, Sweden-based company. Wallden will begin work on Jan. 19. Wallden previously was president and CEO of Pyrosequencing, a position he held since 1997. Previously, he held various R&D and marketing positions within Pharmacia Biotechnology (today Amersham Biosciences), before he was appointed vice president worldwide marketing, sales and support at Pharmacia Biosensor, whose name was changed to Biacore in conjunction with the company’s initial public offering in 1989.

Peter Tattle joins the board of directors of Genta, a Berkeley Heights, NJ-based company. Tattle was previously chairman for pharmaceuticals in the Americas for Johnson & Johnson before retiring in 2001. Tattle currently serves on the boards of Xanthus Life Sciences, DFB Pharmaceuticals, Catalina Marketing, and the Cancer Institute of New Jersey. He replaces Patrick Zenner, who resigned from Genta’s board. Genta is developing RNA and DNA-based medicines.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.